Background SOX9 belongs to the SOX [sry-related highmobility group (HMG) box] family and acts as a transcription factor that plays a central role in the development and differentiation of multiple cell lineages. The aim of this study was to determine whether the GKN1 gene is involved in the development of gastric cancer by regulating SOX9. Methods The effect of GKN1 and b-catenin on SOX9 expression was examined in GKN1 and b-catenin-transfected AGS and MKN-1 gastric cancer cells. SOX9 expression was also determined in gastric cancer tissues and cell lines by Western blot analysis and immunohistochemistry. Results Ectopic expression of b-catenin induced increased expression of SOX9 in AGS cells, whereas GKN1 decreased expression of SOX9 in AGS and MKN-1 cells. In addition, we found an inverse correlation between expression of SOX9 and GKN1 in gastric cancer tissues and cell lines. In immunohistochemistry, nuclear SOX9 expression was detected in 64 (34.6 %) of 185 gastric carcinomas and its expression was closely associated with GKN1 immunonegativity. There was no significant relationship between altered expression of SOX9 protein and clinicopathological parameters including overall survival. Conclusion These data suggest that aberrant SOX9 expression by GKN1 inactivation may be involved in the development of sporadic gastric cancers as an early event.
Introduction
Gastric cancer has a high incidence in Asia and is one of the most common causes of cancer death in this part of the world [1] . It accounts for an estimated 20.8 % of all malignancies, 18.6 % in males and 8.9 % in females of the Korean population. The age-standardized incidence rate of gastric cancer was 63.2 per 100,000 for males and 24.7 per 100,000 for females annually [2] . It is well known that Helicobacter pylori (H. pylori) infection, environmental factors, dietary habits, and genetic factors are involved in gastric carcinogenesis [3] .
b-catenin is a multifunctional protein that plays an important role in the transduction of Wnt signals and in intercellular adhesion by linking the cytoplasmic domain of cadherin [4] . There are several lines of evidence that the Wnt signaling pathway-related genes are involved in human cancer development or progression [5] . Previously, we witnessed frequent loss of gastrokine 1 (GKN1) expression in gastric tumors, including adenoma and cancer, and tumor suppressor activity of GKN1 in a functional analysis [6] . Moreover, GKN1 plays an important role in the epithelial mesenchymal transition (EMT) by re-expression of E-cadherin and decreased expression of b-catenin [7] . Thus, we hypothesized that aberrant expression of SOX9, a target protein of b-catenin, by inactivation of GKN1 is involved in the development of sporadic gastric cancers.
SOX9 belongs to the SOX [sry-related high-mobility group (HMG) box] family and acts as a transcription factor that plays a central role in the development and differentiation of multiple cell lineages [8, 9] . SOX9 has emerged as a modulator of canonical Wnt/b-catenin signaling in diverse development and disease contexts [10] . In human embryonic tissues at 7.5 weeks gestational age, epithelial SOX9 expression is detected in the small intestine and mesodermal SOX9 expression is detected in the posterior region of the stomach at the pyloric area [11] . Numerous studies have demonstrated that SOX9 is involved in carcinogenesis in several types of cancers, including gastric cancers [12, 13] .
Because gastric mucosa with intestinal metaplasia is one of the precancerous lesions of gastric cancer and activation of the Wnt/b-catenin signaling pathway is frequently detected in intestinal-type gastric cancers [3] , we investigated whether GKN1 regulates the expression of SOX9, a downstream molecule of b-catenin, and whether its expression is involved in gastric carcinogenesis. Finally, we found that aberrant SOX9 expression by inactivation of GKN1 contributes to the development of gastric cancer as an early event.
Materials and methods
Cell culture and transfection of GKN1 and SOX9 SNU-1, SNU-216, SNU-484, SNU-620, SNU-638, SNU-668, SNU-719, AGS, and MKN-1 gastric cancer cell lines and HFE-145 immortalized nonneoplastic gastric mucosa cells were cultured at 37°C in 5 % CO 2 in RPMI-1640 medium with 10 % heat-inactivated fetal bovine serum. The complete GKN1 cDNA was cloned into the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). AGS and MKN-1 cells were transfected in 60-mm-diameter dishes with expression plasmids (5 lg total DNA), using lipofectamine plus transfection reagent (Invitrogen) according to the manufacturer's recommendations.
Effects of GKN1 on expression of SOX9 proteins As our previous study showed that GKN1 decreased expression of nuclear b-catenin [7] , we set out to determine if GKN1 is associated with the expression of SOX9 protein. To confirm whether SOX9 is a downstream molecule of b-catenin, we also analyzed the expression of SOX9 protein in AGS cells after transfection with HA-tagged wild and mutant (S37A) b-catenin. Expression of GKN1 and SOX9 proteins was also examined in AGS and MKN-1 cells 24 and 48 h after GKN1 transfection. Cell lysates were separated on a 10 % polyacrylamide gel and transferred onto a Hybond PVDF membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA). After blocking, the membrane was subsequently probed with antibodies against GKN1 and SOX9 proteins. The following antibodies were used: anti-GKN1 (Sigma-Aldrich, St. Louis, MO, USA), anti-SOX9 (Millipore, Billerica, MA, USA), anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-GAPDH (Abcam, Cambridge, UK) and then incubated with anti-mouse IgG conjugated with horseradish peroxidase. The protein bands were detected using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech).
Measurement of SOX9 mRNA expression mRNA expression of GKN1 and SOX9 proteins was also examined in AGS and MKN-1 cells 24 and 48 h after GKN1 transfection. cDNA was synthesized using the reverse transcription kit from the Roche molecular system (Roche, Mannheim, Germany) according to the manufacturer's protocol. For quantitative polymerase chain reaction (QPCR), 50 ng cDNA was amplified using full velocity SYBR Green QPCR Master Mix (Stratagene, La Jolla, CA, USA) and 20 pmol/ll each of forward and reverse primers on the Stratagene Mx 3000P QPCR system with techniques previously published [6] . The specific oligonucleotide primers for mRNA were designed using primer 3 (available: http://frodo.wi.mit.edu/primer3/) on the SOX9 gene. The primer sequences of SOX9 gene were as follows: 5 0 -TACGACTACACCGACCACCA-3 0 and 5 0 -TCAAGGTC-GAGTGAGCTGTG-3 0 . To ensure the fidelity of mRNA extraction and reverse transcription, all samples were subjected to PCR amplification with oligonucleotide primers specific for the constitutively expressed gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and normalized. The primer pair for GAPDH were as follows: 5 0 -AAATCAAGTGGGGCGATGCTG-3 0 and 5 0 -GCAGAGATGATGACCCTTTTG-3 0 . The standard curve method was used for quantification of the relative amounts of gene expression products. This method provides unitless normalized expression values that can be used for direct comparison of the relative amount of mRNA in different samples. All samples were tested in triplicate, and average values were used for quantification.
SOX9 protein expression in gastric cancer cell lines and tissues
We also analyzed the expression of GKN1 and SOX9 proteins in 30 frozen gastric cancers, corresponding noncancerous gastric mucosal tissues, and 10 gastric cancer cell lines by Western blot analysis. These samples were ground to a very fine powder in liquid nitrogen using a pestle and mortar and suspended in an ice-cold Nonidet P-40 lysis buffer supplemented with a 19 protease inhibitor mix (Roche). Cell lysates were separated on 10 % polyacrylamide gel and blotted onto a Hybond-PVDF transfer membrane (Amersham), which had been subsequently probed with anti-GKN1 (Sigma-Aldrich), anti-SOX9 (Millipore), and anti-GAPDH (Abcam), and then incubated with anti-rabbit IgG conjugated with horseradish peroxidase. The protein bands were detected using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech). Approval was obtained from the Institutional Review Board of The Catholic University of Korea, College of Medicine (CUMC09U089).
Expression patterns of SOX9 by immunohistochemistry
For immunohistochemical analysis, tissue microarray recipient blocks were constructed containing 185 gastric cancer tissues from formalin-fixed paraffin-embedded specimens. The 185 cases included 119 men and 66 women with a mean age of 57.7 years at initial diagnosis. Mean tumor size was 6.5 cm. Two tissue cores from each cancer (2 mm in diameter) were placed in a new recipient paraffin block using a commercially available microarray instrument (Beecher Instruments, Micro-Array Technologies, Silver Spring, MD, USA), according to established methods [6] . One cylinder of corresponding noncancerous gastric mucosa adjacent to each tumor was also transferred to the recipient block, and 2-lm sections were cut the day before use and stained according to standard protocols.
To maximize the immunohistochemistry signal, two strategies were used: antigen retrieval in citrate buffer, and signal amplification with biotinylated tyramide, as previously described [6] . The sections were incubated overnight at 4°C with SOX9 antibodies (1/100; Millipore). Detection was carried out using biotinylated goat anti-rabbit antibodies (Sigma), followed by incubation with a peroxidaselinked avidin-biotin complex. Diaminobenzidine was used as a chromogen, and the slides were counterstained with Mayer's hematoxylin. Staining for SOX9 antigen in cancer tissues was considered positive when[30 % of the nucleus was stained positively. The results were reviewed independently by two pathologists. For negative controls, primary antibodies were replaced with nonimmune serum. Approval was obtained from the Institutional Review Board of The Catholic University of Korea, College of Medicine (CUMC09U089).
Statistical analysis
Student's t test was used to analyze the effect of GKN1 on SOX9 mRNA expression. Data are expressed as mean ± SD from at least three independent experiments. The chi-square test for association was used to examine the relationship between SOX9 and GKN1 expression and the clinicopathological parameters. Survival curves were plotted with Kaplan-Meier methods and compared by the log-rank test. Survival data were evaluated using Cox regression analysis. A P value less than 0.05 was considered to be of statistical significance.
Results

Effect of GKN1 on SOX9 expression
To certify the effects of GKN1 on SOX9 expression, we analyzed SOX9 expression in AGS cells transfected with wild and mutant (S37A) b-catenin and GKN1. Interestingly, ectopic expression of both wild and mutant b-catenin induced increased expression of SOX9 protein in AGS cells, but GKN1 markedly inhibited SOX9 expression induced by b-catenin (Fig. 1a) . Next, SOX9 expression was examined in GKN1 transfected AGS and MKN-1 gastric cancer cells by Western blot analysis. As expected, ectopic GKN1 expression reduced SOX9 expression in GKN1-transfected AGS and MKN-1 cells (Fig. 1b) . Moreover, GKN1 significantly decreased SOX9 mRNA expression in GKN1-transfected AGS and MKN-1 cells (P \ 0.05) (Fig. 1c) , suggesting that GKN1 downregulates expression of SOX9, a downstream target of b-catenin.
GKN1 and SOX9 expression in gastric cancer tissues and cell lines
To confirm these results in human gastric cancer tissues and cell lines, we compared GKN1 protein expression with SOX9 in 30 corresponding noncancerous gastric mucosa versus gastric cancer tissues, HFE-145, and 9 gastric cancer cell lines. Expectedly, all 9 gastric cancer cell lines analyzed expressed SOX9 protein, but not GKN1 protein, suggesting that SOX9 protein is completely activated in these gastric cancer cells and that GKN1 expression is inversely associated with expression of SOX9 (Fig. 2a) . When primary gastric cancer tissues were examined by Western blot, 22 (66.7 %) of 30 gastric cancer tissues showed reduction or loss of GKN1 expression (Fig. 2b) . Overexpression of SOX9 was found in 9 (30.0 %) of 30 gastric cancers and, histologically, its expression was detected in 5 (31.3 %), 2 (40 %), and 2 (22.2 %) of 16 intestinal-, 5 diffuse-, and 9 mixed-type gastric cancers, respectively. Of these, 7 (77.8 %) gastric cancer tissues showed reduction or loss of GKN1 expression (Fig. 2b) . To further confirm our results, we recapitulated GKN1 and SOX9 gene expression levels in the large cohort of gastric cancer patients that are available from the National Center for Biotechnology Information (NCBI) gene expression omnibus (GEO) database (accession numbers GSE27342). Consistently, GKN1 gene expression was significantly SOX9 in gastric cancers 249 downregulated, although SOX9 expression was upregulated in gastric cancer cohorts (P \ 0.05) (Fig. 2c) .
Expression patterns of SOX9 by immunohistochemistry
Previously, it has been reported that weak to moderate staining of SOX9 was found in nuclei of normal gastric mucosal cells in the corpus and pyloric region [12] . In this study, we also found a weak to moderate immunopositivity for SOX9 in the nucleus of the neck/isthmus and surface epithelial cells in the corpus and pylorus (Fig. 3) . However, corresponding surrounding normal cells such as lymphocytes and fibroblasts were negative for SOX9. In gastric cancers, overexpression of SOX9 was detected in 64 (34.6 %) of 185 gastric carcinomas (Fig. 3) . SOX9 was strongly expressed in 23 (37.7 %), 33 (35.9 %), and 8 (25.0 %) of 61 intestinal-, 92 diffuse-, and 32 mixed-type gastric cancers, respectively. Statistically, there was no significant relationship between altered SOX9 expression and the clinicopathological parameters, including tumor differentiation, depth of invasion, location, lymph node metastasis, and 5-year survival (chi-square test, P [ 0.05) ( Table 1 ; Fig. 4 ). In addition, a moderate to strong immunopositivity for GKN1 was clearly marked on the cytoplasm of noncancerous gastric mucosal cells, and reduction or loss of GKN1 expression was found in 167 (90.3 %) of 185 gastric cancers (Table 1) . Altered expression of GKN1 was not associated with clinicopathological parameters. When we compared SOX9 expression with GKN1 expression in these cases [6] , 52 (82.8 %) of 64 gastric cancer cases with SOX9 expression showed immunonegativity for GKN1. There was a close inverse correlation between SOX9 and GKN1 expression in gastric cancer (P = 0.006).
Discussion
Gastric cancer is generally believed to be caused by a multistep progression of events triggered by chronic Helicobacter pylori infection. Atrophic gastritis, intestinal metaplasia, and dysplasia represent the different stages of the gastric carcinogenesis cascade [3] . The oncogenic H. pylori strain selectively activates b-catenin in gastric epithelia, and the nuclear accumulation of b-catenin is increased in the gastric epithelium harvested from gerbils infected with the H. pylori strain as well as from persons carrying the cag ? strain [14] . After its translocation into the nucleus, b-catenin binds to members of the Tcf/Lef family, thereby activating target genes including cyclin D1 [15] . Recently, the SOX9 gene was identified as a downstream target of the Wnt pathway [16] ; it was associated with cell proliferation and inhibition of apoptosis [17] . Taken together, these results suggest that aberrant SOX9 expression by b-catenin activation may contribute to the development or progression of gastric cancer.
Canonical b-catenin-Tcf4 complex activity is strictly required for SOX9 expression, and this regulation occurs at the RNA level [16] . The genomic region situated from 200 kb upstream to 100 kb downstream of the SOX9 Fig. 1 Effect of GKN1 and bcatenin on SOX9 expression. a Ectopic expression of both wild-type and mutant (S37A) bcatenin induced increased SOX9 expression in AGS cells, but GKN1 markedly inhibited SOX9 expression induced by wild-type and mutant b-catenin. b Ectopic expression of GKN1 in AGS and MKN-1 gastric cancer cells downregulated SOX9 expression. Blots are representative of at least two individual experiments. c GKN1 significantly downregulated SOX9 mRNA expression (P \ 0.05). Data are expressed as mean ± SD from at least three independent experiments transcriptional unit for putative canonical TCF-binding sites was also identified [16] . Here, we also found that ectopic expression of both wild-type and mutant b-catenin induced increased expression of SOX9 protein in AGS cells (Fig. 1a) . SOX9 is one of the transcriptional target genes of the Wnt signaling pathway and may be a stem cell marker in the intestinal metaplastic mucosa [12, 16] . In addition, SOX9 was associated with cell proliferation and the inhibition of apoptosis in malignant glioma [17] . Previously, we have reported that GKN1, a gastric tumor suppressor, downregulates Wnt signaling pathway including b-catenin and cyclin D1 [7] . Thus, we focused on the effect of GKN1 on SOX9 expression in gastric cancer and its expression in human gastric cancer tissues. First, because inactivation of the GKN1 and the increase of SOX9 expression occur at the normal-gastritis-adenoma transition [6, 16] , we determined SOX9 expression in GKN1-transfected AGS and MKN-1 gastric cancer cells. Expectedly, ectopic GKN1 expression significantly reduced expression of b-catenin and SOX9 (Fig. 1), suggesting that GKN1 may downregulate SOX9 expression by inhibiting the b-catenin signaling pathway. However, it has also been reported that additional regulatory molecules, including miR-145 and NF-jB subunit p65, also contribute to the regulation of SOX9 expression [18, 19] , Thus, additional studies are necessary to verify these initial observations.
Next, we examined whether GKN1 expression is associated with SOX9 expression in 14 gastric cancer cell lines and 30 human gastric cancer tissues. We found that all the gastric cancer cell lines analyzed showed SOX9 expression, but not GKN1 (Fig. 2a) . In gastric cancer tissues, the GKN1 expression level was also inversely correlated with SOX9 expression (Fig. 2b) . To further confirm our results, we recapitulated GKN1 and SOX9 gene expression from the large cohorts of gastric cancer patients that are available from the NCBI GEO database (accession numbers GSE27342). Consistently, GKN1 gene expression was significantly downregulated, although expression of SOX9 gene was significantly upregulated in gastric cancer cohorts c Recapitulated GKN1 and SOX9 gene expression levels in the large cohort of gastric cancer patients. One set of microarray data was obtained from the NCBI GEO database (accession numbers GSE27342). The relative expression levels of GKN1 and SOX9 mRNA in noncancerous (Normal) and gastric cancer (Tumor) tissues is illustrated by scatter plot. The median expression level of each group is indicated by horizontal lines. Gene expression levels are shown on the ordinate (log 2 intensity). The differential GKN1 and SOX9 expression for these two categories was determined by the unpaired t test (P \ 0.05, two-tailed), respectively SOX9 in gastric cancers 251 (Fig. 2c) . Statistically, there was a significant correlation between GKN1 and SOX9 expression in gastric cancer tissues (P \ 0.05), suggesting that GKN1 functions as a SOX9 inhibitor.
We also analyzed SOX9 expression patterns in 185 gastric cancers by immunohistochemistry. Basal expression patterns of SOX9 were similar in the corpus and pylorus, consistent with that of a Japanese study [12, 13] . SOX9 overexpression was detected in 64 (34.6 %) of 185 gastric cancers (Fig. 3) and was closely associated with GKN1 immunonegativity (P = 0.006). Statistically, there was no significant relationship between aberrant SOX9 expression and the clinicopathological parameters, including depth of invasion and overall survival (P [ 0.05) ( Table 1) . Although Kimura et al. have reported that all the intestinal-type gastric cancers expressed SOX9, we found that diffuse-type gastric cancer also showed overexpression of SOX9 protein (Fig. 3) . In colon cancer [20, 21] and breast cancer [22] , SOX9 overexpression was correlated with cancer progression and a poor overall prognosis. In contrast, it has been reported that SOX9 is related to the development of gastric cancer, but it decreases through progression of gastric cancer [13] . Radulescu et al. [23] have recently reported that the altered Wnt/b-catenin signaling pathway in the stomach epithelium rapidly generates an initiating step in gastric tumorigenesis. In addition, there was no significant association between high SOX9 expression and tumor grade, Dukes stage, and survival in colorectal cancer [24] . Thus, our results further support that SOX9 overexpression by GKN1 inactivation may contribute to the development of gastric cancer as an early event. However, because GKN1 also plays a role in the progression of gastric cancer by regulating expression of E-cadherin and representative EMT markers including bcatenin, slug, snail, fibronectin [7] , and SOX9 expression was decreased through progression of gastric cancer [13] , further studies are strongly needed to clarify the regulatory mechanism of SOX9 by GKN1 in the progression of gastric cancer.
In conclusion, ectopic GKN1 expression resulted in inhibition of SOX9 expression in AGS and MKN-1 gastric cancer cells. We detected an inverse correlation between SOX9 and GKN1 expression in gastric cancer tissues and cell lines. Additionally, aberrant SOX9 expression was observed in 64 (34.6 %) of gastric cancers, and there was no statistical significance between SOX9 expression and overall survival. Thus, we conclude that upregulation of SOX9 by GKN1 inactivation may contribute to the development of gastric cancer as an early event. Additional functional and translational studies of the SOX9 will broaden our understanding of the pathogenesis of gastric cancer and provide us with novel diagnostic and therapeutic modalities in gastric cancer.
